Novo Nordisk Foundation chair Lars Rebien Sørensen now seeks the chair of Novo Nordisk’s board. Business historian Kurt Jacobsen calls the bid “extremely unusual” in Denmark and a gamble that concentrates accountability squarely on Rebien.
Tensions have built for months: the foundation used its voting control (77% of votes on 28.1% ownership) to oust CEO Lars Fruergaard Jørgensen; Mike Doustdar took over on 7 August, and Rebien gained a board observer seat. Meanwhile Eli Lilly intensifies competition, Wegovy faces copycat products, and about 9,000 jobs are being cut worldwide—some 5,000 in Denmark.
So…:
In which situations should you particularly assert your management authority?
Source:
Picture: